Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04892706 · ClinicalTrials.gov registry record · Phase 2
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
A Phase 2 study of Acne Vulgaris, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 686
- Enrollment target
- 20
- Study locations
NCT04892706: Completed Phase 2 study of Acne Vulgaris, sponsored by Bausch Health Americas.
NCT04892706 is a Phase 2 study of Acne Vulgaris that has completed, run by Bausch Health Americas. The registered enrollment target is 686 participants, above the 265-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (159% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04892706, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 686 participants
- Enrollment target
- 20
- Study locations
Study Summary
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
Primary Outcome
Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.
Conditions Studied
Interventions
- DRUG IDP-126 Gel
- DRUG IDP-126 Vehicle Gel
- DRUG Epiduo® Forte Gel
Study Locations (20)
Florida
- Bausch Site 105 - Boynton Beach
- Bausch Site 126 - Clearwater
- Bausch Site 135 - North Miami Beach
- Bausch Site 143 - Sanford
- Bausch Site 102 - Tampa
- Bausch Site 104 - West Palm Beach
- Bausch Site 122 - West Palm Beach
California
- Bausch Site 110 - Fremont
- Bausch Site 101 - Manhattan Beach
- Bausch Site 106 - San Diego
- Bausch Site 112 - San Diego
- Bausch Site 128 - San Diego
Arkansas
- Bausch Site 134 - Bryant
- Bausch Site 118 - Rogers
Louisiana
- Bausch Site 139 - Mandeville
- Bausch Site 121 - Metairie
Georgia
- Bausch Site 124 - Newnan
Idaho
- Bausch Site 127 - Boise
Kentucky
- Bausch Site 129 - Louisville
Maryland
- Bausch Site 116 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 2 |
What the finished NCT04892706 record still lists
NCT04892706 is an interventional study that assigns participants to a tested intervention. The registered 686 participants enrollment target is mid-sized for trials with a published cap, above the 265-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (159% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which IDP-126 Gel is the first listed.
NCT04892706 names 20 study sites across 8 states, led by Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04892706 about?
NCT04892706 is a clinical study titled "Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel". The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
What is the current status of trial NCT04892706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 686 participants. The study started on 2021-06-11. Estimated completion is 2022-09-28.
What conditions does trial NCT04892706 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04892706?
The interventions under investigation include: IDP-126 Gel (DRUG), IDP-126 Vehicle Gel (DRUG), Epiduo® Forte Gel (DRUG).
Who is sponsoring clinical trial NCT04892706?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04892706 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04892706's enrollment target sits among peer trials
686 10th of 67 higher than 58 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- NCT06618274 · 686 participants · NA
Effectiveness of Central Oncology Navigation and the Use of an ORN
- NCT06899126 · 686 participants · Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI